{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T16:49:09Z","timestamp":1780937349123,"version":"3.54.1"},"reference-count":30,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,2,14]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Relapse after allogeneic stem cell transplantation (allo-SCT) remains the primary cause of\u00a0treatment failure. A second SCT can result in long-term survival in a subset of patients, but the relapse rate remains high. We conducted a single-center, phase 1, modified 3\u00a0+ 3 dose-escalation study of the feasibility of combining intensity-modulated total marrow irradiation (IM-TMI) with fludarabine and melphalan for conditioning. Between December 2015 and May 2020, 21 patients with relapsed hematologic disease undergoing second or greater allo-SCT were treated with IM-TMI doses of 6 Gy, 9 Gy, or 12 Gy. Dose-limiting toxicity was defined as a grade 3 or higher treatment-related adverse event; mucositis was the primary dose-limiting toxicity. The median times to neutrophil and platelet engraftment were 10 and 18 days, respectively. The 1-year cumulative incidence of graft-versus-host disease was 65% (95% confidence interval CI, 38-83). The nonrelapse mortality at 2 years was 17% (95% CI, 4-39). Cumulative incidence of relapse at 2 years was 35% (95% CI, 13-58). Two-year progression-free survival and overall survival were 48% and 50%. We conclude that combining IM-TMI with fludarabine-melphalan is feasible. We recommend 12 Gy of IM-TMI with fludarabine-melphalan for second SCT, although 9 Gy may be used for older or underweight patients.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022007530","type":"journal-article","created":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T00:07:25Z","timestamp":1658189245000},"page":"285-292","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":8,"title":["A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8412-4470","authenticated-orcid":false,"given":"Misha C.","family":"Tran","sequence":"first","affiliation":[{"name":"1Department of Medicine, Section of Hematology\/Oncology, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin","family":"Hasan","sequence":"additional","affiliation":[{"name":"2Department of Radiation & Cellular Oncology, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Wang","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Section of Hematology\/Oncology, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamil","family":"Yenice","sequence":"additional","affiliation":[{"name":"2Department of Radiation & Cellular Oncology, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Partouche","sequence":"additional","affiliation":[{"name":"2Department of Radiation & Cellular Oncology, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Stock","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Section of Hematology\/Oncology, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9168-3203","authenticated-orcid":false,"given":"Richard A.","family":"Larson","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Section of Hematology\/Oncology, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satyajit","family":"Kosuri","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Section of Hematology\/Oncology, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"LaBelle","sequence":"additional","affiliation":[{"name":"3Department of Pediatrics, Section of Hematology, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Kline","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Section of Hematology\/Oncology, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2719-0580","authenticated-orcid":false,"given":"Peter A.","family":"Riedell","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Section of Hematology\/Oncology, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0803-9607","authenticated-orcid":false,"given":"Andrew S.","family":"Artz","sequence":"additional","affiliation":[{"name":"4Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Weichselbaum","sequence":"additional","affiliation":[{"name":"2Department of Radiation & Cellular Oncology, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Bishop","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Section of Hematology\/Oncology, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bulent","family":"Aydogan","sequence":"additional","affiliation":[{"name":"2Department of Radiation & Cellular Oncology, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3190-7807","authenticated-orcid":false,"given":"Hongtao","family":"Liu","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Section of Hematology\/Oncology, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,1,25]]},"reference":[{"issue":"7","key":"2023021422370294200_","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1038\/s41409-021-01227-8","article-title":"Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years","volume":"56","author":"Passweg","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"22","key":"2023021422370294200_","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1004383","article-title":"Reduced mortality after allogeneic hematopoietic-cell transplantation","volume":"363","author":"Gooley","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2023021422370294200_","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1586\/eci.11.24","article-title":"Clinical options after failure of allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies","volume":"7","author":"Petrovic","year":"2011","journal-title":"Expert Rev Clin Immunol"},{"issue":"2","key":"2023021422370294200_","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1200\/JCO.1993.11.2.304","article-title":"Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens","volume":"11","author":"Radich","year":"1993","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2023021422370294200_","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/sj.bmt.1705011","article-title":"Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia","volume":"36","author":"Hosing","year":"2005","journal-title":"Bone Marrow Transplant"},{"issue":"16","key":"2023021422370294200_","doi-asserted-by":"crossref","first-page":"3675","DOI":"10.1200\/JCO.2001.19.16.3675","article-title":"Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European Cooperative Group for Blood and Marrow Transplantation","volume":"19","author":"Bosi","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"2023021422370294200_","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/sj.bmt.1704645","article-title":"Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant","volume":"34","author":"Eapen","year":"2004","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"2023021422370294200_","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1182\/blood-2011-08-375840","article-title":"Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation","volume":"119","author":"Schmid","year":"2012","journal-title":"Blood"},{"issue":"24","key":"2023021422370294200_","doi-asserted-by":"crossref","first-page":"5728","DOI":"10.1200\/JCO.2005.15.602","article-title":"Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome","volume":"23","author":"van Besien","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2023021422370294200_","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.bbmt.2009.01.021","article-title":"Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes","volume":"15","author":"van Besien","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"2023021422370294200_","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1182\/blood.V76.9.1867.1867","article-title":"Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens","volume":"76","author":"Clift","year":"1990","journal-title":"Blood"},{"issue":"2","key":"2023021422370294200_","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.radonc.2011.06.005","article-title":"Dosimetric study of volumetric modulated arc therapy fields for total marrow irradiation","volume":"102","author":"Han","year":"2012","journal-title":"Radiother Oncol"},{"issue":"5","key":"2023021422370294200_","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1177\/153303460600500508","article-title":"Linac-based intensity modulated total marrow irradiation (IM-TMI)","volume":"5","author":"Aydogan","year":"2006","journal-title":"Technol Cancer Res Treat"},{"issue":"7","key":"2023021422370294200_","first-page":"2196","article-title":"Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia","volume":"93","author":"Ringden","year":"1999","journal-title":"Nordic Bone Marrow Transplantation Group. Blood"},{"issue":"3","key":"2023021422370294200_","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.ijrobp.2019.02.034","article-title":"Higher reported lung dose received during total body irradiation for allogeneic hematopoietic stem cell transplantation in children with acute lymphoblastic leukemia is associated with inferior survival: a report from the Children\u2019s Oncology Group","volume":"104","author":"Esiashvili","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"12","key":"2023021422370294200_","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/j.bbmt.2014.09.005","article-title":"Combination of linear accelerator-based intensity-modulated total marrow irradiation and myeloablative fludarabine\/busulfan: a phase I study","volume":"20","author":"Patel","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"23","key":"2023021422370294200_","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","article-title":"Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation","volume":"123","author":"Armand","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2023021422370294200_","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2023021422370294200_","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"2023021422370294200_","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"issue":"12","key":"2023021422370294200_","doi-asserted-by":"crossref","first-page":"5609","DOI":"10.1118\/1.2990779","article-title":"Feasibility study for linac-based intensity modulated total marrow irradiation","volume":"35","author":"Wilkie","year":"2008","journal-title":"Med Phys"},{"issue":"4","key":"2023021422370294200_","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/j.ijrobp.2010.06.029","article-title":"Linear accelerator-based intensity-modulated total marrow irradiation technique for treatment of hematologic malignancies: a dosimetric feasibility study","volume":"79","author":"Yeginer","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"2023021422370294200_","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.3109\/10428190903200790","article-title":"Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence","volume":"50","author":"van Besien","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2023021422370294200_","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.3109\/10428194.2012.739688","article-title":"Immune reconstitution after combined haploidentical and umbilical cord blood transplant","volume":"54","author":"Jain","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2023021422370294200_","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40164-018-0125-6","article-title":"Outcomes following second allogeneic stem cell transplant for disease relapse after T cell depleted transplant correlate with remission status and remission duration after the first transplant","volume":"8","author":"Fan","year":"2019","journal-title":"Exp Hematol Oncol"},{"issue":"3","key":"2023021422370294200_","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.bbmt.2005.10.026","article-title":"Targeted total marrow irradiation using three-dimensional image-guided tomographic intensity-modulated radiation therapy: an alternative to standard total body irradiation","volume":"12","author":"Wong","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2023021422370294200_","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1182\/blood-2010-06-288357","article-title":"Phase 1\/2 trial of total marrow and lymph node irradiation to augment reduced-intensity transplantation for advanced hematologic malignancies","volume":"117","author":"Rosenthal","year":"2011","journal-title":"Blood"},{"issue":"8","key":"2023021422370294200_","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.jtct.2021.05.007","article-title":"Outcomes of second allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia","volume":"27","author":"Yalniz","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"2023021422370294200_","doi-asserted-by":"crossref","first-page":"e14199","DOI":"10.1111\/ctr.14199","article-title":"Second allogeneic hematopoietic stem cell transplantation in patients with acute leukemia relapsed after allogeneic hematopoietic stem cell transplantation","volume":"35","author":"Choi","year":"2021","journal-title":"Clin Transplant"},{"issue":"12","key":"2023021422370294200_","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41408-019-0251-3","article-title":"Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the Acute Leukemia Working Party of EBMT","volume":"9","author":"Shimoni","year":"2019","journal-title":"Blood Cancer J"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/3\/285\/2033416\/blooda_adv-2022-007530-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/3\/285\/2033416\/blooda_adv-2022-007530-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T18:37:21Z","timestamp":1700851041000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/3\/285\/485950\/A-phase-1-trial-utilizing-TMI-with-fludarabine"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,25]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,2,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022007530","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,25]]}}}